Preliminary of pharmacokinetics study of brown seaweed (turbinaria decurrens bory) extract in colon cancer model mice induced by aom (azoxymethane) and dss (dextran sodium sulphate)

Nurul Qurrota’Ayun, Astria Deviyani Zakaria, Anton Bahtiar

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Introduction: Colon Cancer is one of leading cancer that causes morbidity and mortality worldwide, causes 774,000 deaths. Fucoxanthin contained brown seaweed Bory) extracts showed cytotoxic activity by and study, including colon cancer. This study aims to examine the absorption profile of fucoxanthin in blood plasma on colon cancer model mice. Methods: Mice were induced by azoxymethane (AOM) and two cycle dextran sulfate sodium (DSS). Mice were given an extract of brown seaweed Bory that contain fucoxanthin. Fucoxanthin content in blood plasma analyzed using mobile phase methanol: acetonitrile by Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) analysis. Results: The maximum concentration of fucoxanthin in blood was at 4 hours after administration, and the plasma concentration is 2.15 nmol/L, T1/2 6.25 h, and AUC 10.75 nmol/L/h Conclusions: The method was applied successfully in a pharmacokinetic study and the resulting oral brown seaweed bioavailability calculated.

Original languageEnglish
Pages (from-to)567-570
Number of pages4
JournalPharmacognosy Journal
Volume10
Issue number3
DOIs
Publication statusPublished - 1 May 2018

Keywords

  • Brown seaweed
  • Colon cancer
  • Fucoxanthin

Fingerprint

Dive into the research topics of 'Preliminary of pharmacokinetics study of brown seaweed (turbinaria decurrens bory) extract in colon cancer model mice induced by aom (azoxymethane) and dss (dextran sodium sulphate)'. Together they form a unique fingerprint.

Cite this